[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-hemodialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-hemodialysis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100645632","pilot-trial-of-oral-sodium-bicarbonate-versus-higher-dialysate-bicarbonate-in-hemodialysis-patients-with-metabolic-acidosis-100645632",false,"NCT07688434","Pilot Trial of Oral Sodium Bicarbonate Versus Higher Dialysate Bicarbonate in Hemodialysis Patients With Metabolic Acidosis","Comparative Pilot Trial of Oral Sodium Bicarbonate Versus Increased Dialysate Bicarbonate in Chronic Hemodialysis Patients With Metabolic Acidosis","Bicarbonate-HD","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Chronic hemodialysis for at least 3 months.\n* Stable hemodialysis prescription: 3 times a week, high-flux dialyzers, no major change in dialysis prescription in the previous weeks.\n* Predialysis low \"alkaline reserves\" (serum bicarbonate concentration) according to the operational threshold used in the unit (e.g., \"alkaline reserves\" \\\u003C 22 mmol\u002FL), consistent with KDIGO 2017 definition of metabolic acidosis.\n* Ability to give written informed consent.\n\nFor the observational group:\n\n* Age ≥ 18 years.\n* Chronic hemodialysis for at least 3 months.\n* Hemodialysis 3 times a week, high-flux dialyzers.\n* Predialysis \"alkaline reserves\" considered stable and within the locally defined normal range (≥ 22mmol\u002FL).\n* Ability to give written informed consent.\n\nExclusion Criteria:\n\n* Recent hemodynamic instability (e.g., repeated intradialytic hypotension or unstable blood pressure in the previous weeks).\n* Recent hospitalization for an acute condition.\n* Acute infection or major intercurrent acute event at the time of screening.\n* Major change in dialysis prescription in the 2 weeks prior to inclusion (e.g., change in dialysis schedule, duration, or dialysate composition outside the study protocol).\n* Severe digestive disorders limiting oral intake (e.g., persistent vomiting, severe malabsorption, or any condition preventing safe oral Bicardis administration).\n* Known hypernatremia or high risk of uncontrolled sodium and fluid overload (as judged by the investigator).\n* Severe uncontrolled hypercalcemia or hypocalcemia.\n* Any condition that, in the investigator's judgment, would preclude safe participation or interfere with study procedures (e.g., very limited life expectancy, inability to attend scheduled visits).\n* Refusal to participate or inability to provide written informed consent.","ALL","18 Years",{"count":20,"type":21},37,"ESTIMATED","INTERVENTIONAL",[24],"NA","Metabolic acidosis is frequent in chronic hemodialysis patients and is associated with adverse clinical outcomes. Two commonly used strategies to correct acidosis are oral sodium bicarbonate supplementation and increasing the bicarbonate concentration of the dialysate, but their comparative effectiveness and tolerance in routine care remain uncertain. This pilot, prospective, randomized, open-label, single-center trial will compare oral sodium bicarbonate versus higher dialysate bicarbonate in chronic hemodialysis patients with metabolic acidosis, using predialysis plasma bicarbonate concentrations, so-called \"reserves alcalines\" or \"alkaline reserves\" in local laboratory reports, as a pragmatic marker of acid-base status.\n\nApproximately 30 acidotic patients (serum bicarbonate \\\u003C 22 mmol\u002FL) will be randomized 1:1 to receive either oral sodium bicarbonate or an increase in dialysate bicarbonate for 6 weeks. An additional non-acidotic observational group will provide descriptive reference data. The primary outcome is the change in predialysis serum bicarbonate from baseline (Day 0) to Day 42 between the two randomized arms. Secondary outcomes include the proportion of patients reaching target serum bicarbonate levels, the weekly kinetics of correction, dialysis adequacy (Kt\u002FV and online clearance monitoring), intradialytic tolerance (blood pressure, cramps, hypotension, symptoms), sodium-related safety (natremia, interdialytic weight gain), and the effects of acidosis correction on nutritional and bone-mineral metabolism, including changes in serum albumin, calcium, phosphorus, and parathyroid hormone (PTH). Feasibility indicators such as recruitment, retention, adherence to treatment and dialysate adjustment, and data completeness will also be described to inform the design of a larger definitive trial.",[27,28,29],"End-stage Renal Disease (ESRD)","Chronic Hemodialysis","Metabolic Acidosis",[31,32,29,33,34,35,36],"Hemodialysis","End-Stage Renal Disease","Oral sodium Bicarbonate","Dialysate Bicarbonate","Pilot Trial","Bicarbonate Supplementation","NOT_YET_RECRUITING","2026-07-18",{"date":40,"type":41},"2026-07-21","ACTUAL",{"date":43,"type":21},"2026-07",{"date":45,"type":21},"2026-09",{"name":47,"class":48},"University of Sfax","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":49},"100639360","comparison-of-citrate-and-heparin-anticoagulation-during-postdilution-hemodiafiltration-100639360","NCT07618858","Comparison of Citrate and Heparin Anticoagulation During Postdilution Hemodiafiltration","Efficiency and Biocompatibility of Postdilution Hemodiafiltration Using Different Anticoagulation Methods: A Randomized Crossover Clinical Trial","CITRA-HDF","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End-stage kidney disease requiring maintenance postdilution hemodiafiltration\n* Stable chronic hemodialysis treatment three times weekly\n* Functional arteriovenous fistula\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation therapy\n* Dual antiplatelet therapy\n* Significant coagulopathy\n* Active bleeding\n* Acute kidney injury",{"count":59,"type":21},20,[24],"This randomized crossover clinical trial will compare regional citrate anticoagulation (RCA) and standard heparin anticoagulation (HA) during postdilution hemodiafiltration (HDF) in chronic dialysis patients with end-stage kidney disease.\n\nThe primary aim of the study is to evaluate biocompatibility during HDF by measuring markers of complement activation (C3a), platelet activation (PF4), and coagulation activation (thrombin-antithrombin complex, TAT).\n\nSecondary aims include comparison of solute removal efficiency, including beta-2 microglobulin, phosphate, and urea removal, as well as assessment of citrate, calcium, and magnesium kinetics during citrate anticoagulation.\n\nTwenty adult chronic dialysis patients will undergo two study HDF procedures in randomized order: one procedure using heparin anticoagulation and one procedure using regional citrate anticoagulation with a one-week interval between procedures.\n\nThe study aims to improve understanding of the effects of anticoagulation methods on hemodiafiltration biocompatibility and dialysis efficiency and may contribute to optimization of citrate anticoagulation protocols in chronic hemodiafiltration patients.",[63,64,28,65],"End-Stage Kidney Disease","Hemodiafiltration","Renal Failure",[67,68,64,69,70,71,72,73,74,75,76],"Citrate anticoagulation","Heparin anticoagulation","Dialysis","Biocompatibility","Beta-2 microglobulin","Complement activation","Regional citrate anticoagulation","Chronic dialysis","Thrombin-antithrombin complex","Platelet factor 4","2026-05-27",{"date":79,"type":41},"2026-06-01",{"date":81,"type":21},"2026-06-05",{"date":83,"type":21},"2027-04-01",{"name":85,"class":48},"University Medical Centre Ljubljana",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":49},"100558844","effect-of-renal-denervation-on-bood-pressure-in-patients-on-hemodialysis-100558844","NCT06556407","Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis","Effect of Renal Denervation on Blood Pressure in Patients With Treatment Resistant Hypertension, End-stage Chronic Kidney Disease and Hemodialysis","RDN-HD","Inclusion Criteria:\n\n* Uncontrolled treatment resistant hypertension (despite intake of 3 different classes of antihypertensive medications) confirmed by 24-h ambulatory blood pressure according to current guidelines (ESH 2023) (office blood pressure ≥ 140\u002F and\u002F or ≥ 90 mmHg and ambulatory blood pressure ≥ 130\u002F and\u002For ≥ 80 mmHg\n* end-stage renal disease on chronic hemodialysis\n* Stable hemodialysis regime for at least 3 months based on the decision of the treating physician\n* Patient is adhering to a stable drug regimen without changes for a minimum of 4 weeks.\n* Individual is ≥ 18 years of age, male and female patients are included.\n\nExclusion Criteria:\n\n* Episodes of sustained systolic and\u002For diastolic hypotension according to 24-h ambulatory blood pressure or dialysis protocols which in the eyes of the treating physician would interfere with a safe renal denervation treatment of the patient\n* Known hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which in the eyes of the interventionalist would interfere with safe catheter placement\n* Prior renal denervation procedure\n* Anatomic or functional solitary kidney, kidney transplantation\n* Severe atherosclerotic disease or artery calcification preventing the assessment of reliable BP measurements\n* Endocrine hypertension other than obstructive sleep apnea\n* Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 3 months of the screening visit\n* Acute episode of systemic and renal disease requiring uptitration of any immunosuppressive drug regimen within the last 3 months\n* Subject is pregnant, nursing, or intends to become pregnant\n* Enrollment in another interventional research protocol.\n* Any condition that, at the discretion of the investigator, would preclude participation in the study (e.g. non-adherence)","99 Years",{"count":96,"type":21},12,[24],"The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.",[100,28],"Treatment Resistant Hypertension","RECRUITING","2025-09-22",{"date":104,"type":41},"2025-09-26",{"date":106,"type":41},"2024-03-04",{"date":108,"type":21},"2026-12-01",{"name":110,"class":48},"University of Erlangen-Nürnberg Medical School"]